Kardas Przemysław, Bago Martina, Barnestein-Fonseca Pilar, Garuolienė Kristina, Granas Anne Gerd, Gregório João, Hadžiabdić Maja Ortner, Kostalova Barbora, Leiva-Fernández Francisca, Lewek Pawel, Mala-Ladova Katerina, Schneider Marie Paule, van Boven Job F M, Volmer Daisy, Ziampara Ioli, Ágh Tamás
Medication Adherence Research Centre, Department of Family Medicine, Medical University of Lodz, Lodz, Poland.
Reference Center of Pharmacoepidemiology, Research and Teaching Department, Andrija Stampar Teaching Institute of Public Health, Zagreb, Croatia.
Front Pharmacol. 2022 Aug 11;13:944829. doi: 10.3389/fphar.2022.944829. eCollection 2022.
Medication non-adherence jeopardises the effectiveness of chronic therapies and negatively affects financial sustainability of healthcare systems. Available medication adherence-enhancing interventions (MAEIs) are utilised infrequently, and even more rarely reimbursed. The aim of this paper was to review reimbursed MAEIs across selected European countries. Data on reimbursed MAEIs were collected from European countries at the ENABLE Cost Action expert meeting in September 2021. The identified MAEIs were analysed and clustered according to their characteristics, direct vs. indirect relation to adherence, and the targeted adherence phase. Out of 12 contributing countries, 10 reported reimbursed MAEIs, 28 in total, of which 20 were identified as MAEIs targeting adherence directly. Reimbursed MAEIs were most often performed by either doctors ( = 6), nurses ( = 6), or pharmacists ( = 3). The most common types of MAEIs were education ( = 6), medication regimen management ( = 5), and adherence monitoring feedback ( = 4). Only seven reimbursed MAEIs were technology-mediated, whereas 11 addressed two interlinked phases of medication adherence, , implementation and persistence. Our review highlights the scarcity of reimbursed MAEIs across the selected European countries, and calls for their more frequent use and reimbursement.
药物治疗依从性差会危及慢性治疗的效果，并对医疗保健系统的财务可持续性产生负面影响。现有的提高药物治疗依从性的干预措施（MAEIs）很少被使用，获得报销的情况更是罕见。本文的目的是回顾选定欧洲国家报销的MAEIs。关于报销的MAEIs的数据是在2021年9月的ENABLE成本行动专家会议上从欧洲国家收集的。根据其特征、与依从性的直接或间接关系以及目标依从阶段，对确定的MAEIs进行了分析和分类。在12个参与国家中，10个国家报告了报销的MAEIs，总共28种，其中20种被确定为直接针对依从性的MAEIs。报销的MAEIs大多由医生（=6）、护士（=6）或药剂师（=3）进行。最常见的MAEIs类型是教育（=6）、药物治疗方案管理（=5）和依从性监测反馈（=4）。只有7种报销的MAEIs是由技术介导的，而11种涉及药物治疗依从性的两个相互关联的阶段，即实施和持续。我们的综述强调了选定欧洲国家报销的MAEIs的稀缺性，并呼吁更频繁地使用和报销这些措施。
